- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYXONE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,688 | +3,40 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| NOVAVAX | 8,457 | +0,26 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 0,795 | -19,70 % | COSCIENS Biopharma Inc.: COSCIENS Provides Strategic Update | TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company") today announced that the Company has made a strategic decision... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,210 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office | Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector... ► Artikel lesen | |
| ARGENX | 598,60 | +1,39 % | ARGENX SE - 20-F, Annual and transition report of foreign private issuers | ||
| ORAGENICS | 0,750 | 0,00 % | ORAGENICS INC - 10-K, Annual Report | ||
| LEXICON PHARMACEUTICALS | 1,368 | -1,87 % | Lexicon Pharmaceuticals, Inc.: Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement | THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) ("Lexicon") today announced the closing of its previously announced underwritten public offering... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,310 | +3,61 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note | ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,825 | +8,55 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - AACR 2026 PREVIEW: CSTONE TO PRESENT PRECLINICAL DATA FOR THREE PROPRIETARY PIPELINE ASSETS | ||
| SERES THERAPEUTICS | 7,980 | +2,44 % | Seres Therapeutics terminiert Hauptversammlung für den 9. Juni 2026 | ||
| KRYSTAL BIOTECH | 221,80 | +0,27 % | Krystal Biotech, Inc.: Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results | $107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 1,199 | -2,44 % | GenScript Biotech Corporation: GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth | Group PerformanceRevenue: US$959.5 million, +61.4% year-on-yearGross profit: US$553.2 million, +103.3% year-on-yearAdjusted net profit: US$230.3 million, +285.0% year-on-yearBusiness Units'... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 6,200 | -0,80 % | Jefferies startet Aligos-Aktie mit "Kaufen" und sieht Potenzial in Hepatitis-B-Medikament | ||
| Q32 BIO | 5,100 | -12,07 % | Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update | -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 22,905 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting |
Das Unternehmen CYXONE AB kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.